Cargando…
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. Thi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146416/ https://www.ncbi.nlm.nih.gov/pubmed/37110201 http://dx.doi.org/10.3390/metabo13040543 |
_version_ | 1785034576010149888 |
---|---|
author | Eatmann, Ahmed Ismail Hamouda, Esraa Hamouda, Heba Farouk, Hossam Khaled Jobran, Afnan W. M. Omar, Abdallah A. Madeeh, Alyaa Khaled Al-dardery, Nada Mostafa Elnoamany, Salma Abd-Elnasser, Eman Gamal Koraiem, Abdullah Muhammed Ahmed, Alhassan Ali Abouzid, Mohamed Karaźniewicz-Łada, Marta |
author_facet | Eatmann, Ahmed Ismail Hamouda, Esraa Hamouda, Heba Farouk, Hossam Khaled Jobran, Afnan W. M. Omar, Abdallah A. Madeeh, Alyaa Khaled Al-dardery, Nada Mostafa Elnoamany, Salma Abd-Elnasser, Eman Gamal Koraiem, Abdullah Muhammed Ahmed, Alhassan Ali Abouzid, Mohamed Karaźniewicz-Łada, Marta |
author_sort | Eatmann, Ahmed Ismail |
collection | PubMed |
description | Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further. |
format | Online Article Text |
id | pubmed-10146416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101464162023-04-29 Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview Eatmann, Ahmed Ismail Hamouda, Esraa Hamouda, Heba Farouk, Hossam Khaled Jobran, Afnan W. M. Omar, Abdallah A. Madeeh, Alyaa Khaled Al-dardery, Nada Mostafa Elnoamany, Salma Abd-Elnasser, Eman Gamal Koraiem, Abdullah Muhammed Ahmed, Alhassan Ali Abouzid, Mohamed Karaźniewicz-Łada, Marta Metabolites Review Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further. MDPI 2023-04-11 /pmc/articles/PMC10146416/ /pubmed/37110201 http://dx.doi.org/10.3390/metabo13040543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Eatmann, Ahmed Ismail Hamouda, Esraa Hamouda, Heba Farouk, Hossam Khaled Jobran, Afnan W. M. Omar, Abdallah A. Madeeh, Alyaa Khaled Al-dardery, Nada Mostafa Elnoamany, Salma Abd-Elnasser, Eman Gamal Koraiem, Abdullah Muhammed Ahmed, Alhassan Ali Abouzid, Mohamed Karaźniewicz-Łada, Marta Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview |
title | Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview |
title_full | Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview |
title_fullStr | Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview |
title_full_unstemmed | Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview |
title_short | Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview |
title_sort | potential use of thalidomide in glioblastoma treatment: an updated brief overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146416/ https://www.ncbi.nlm.nih.gov/pubmed/37110201 http://dx.doi.org/10.3390/metabo13040543 |
work_keys_str_mv | AT eatmannahmedismail potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT hamoudaesraa potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT hamoudaheba potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT faroukhossamkhaled potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT jobranafnanwm potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT omarabdallaha potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT madeehalyaakhaled potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT aldarderynadamostafa potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT elnoamanysalma potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT abdelnasseremangamal potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT koraiemabdullahmuhammed potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT ahmedalhassanali potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT abouzidmohamed potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview AT karazniewiczładamarta potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview |